Better Pharmaceuticals ETF: VanEck's PPH vs. Invesco PJP
VanEck offers lower costs and double the dividend yield, while Invesco delivered stronger 1-year returns with more balanced holdings.
Overview
The VanEck Pharmaceutical ETF (NASDAQ:PPH) provides a lower-cost entry and higher yield than the Invesco Pharmaceuticals ETF (NYSEMKT:PJP), which has shown stronger 1-year returns and more concentrated top holdings.
These ETFs target the pharmaceutical industry but take different paths. While they both focus on the research and distribution of drugs, their portfolios and cost structures vary significantly. This comparison examines how they stack up on costs, historical risk, and portfolio concentration as of Sept. 29, 2026, to help determine which strategy aligns with an investor's goals.
Details
Beta measures price volatility relative to the S&P 500; beta is calculated from monthly returns over the available fund history (up to five years). The 1-year return represents total return over the trailing 12 months. Dividend yield is the trailing-12-month distribution yield.
Source
Originally published at www.fool.com.